SG11202104197PA - Methods and systems for manufacturing hematopoietic lineage cells - Google Patents
Methods and systems for manufacturing hematopoietic lineage cellsInfo
- Publication number
- SG11202104197PA SG11202104197PA SG11202104197PA SG11202104197PA SG11202104197PA SG 11202104197P A SG11202104197P A SG 11202104197PA SG 11202104197P A SG11202104197P A SG 11202104197PA SG 11202104197P A SG11202104197P A SG 11202104197PA SG 11202104197P A SG11202104197P A SG 11202104197PA
- Authority
- SG
- Singapore
- Prior art keywords
- systems
- methods
- lineage cells
- hematopoietic lineage
- manufacturing
- Prior art date
Links
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749947P | 2018-10-24 | 2018-10-24 | |
PCT/US2019/057929 WO2020086889A1 (fr) | 2018-10-24 | 2019-10-24 | Procédés et systèmes de fabrication de cellules de lignée hématopoïétique |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104197PA true SG11202104197PA (en) | 2021-05-28 |
Family
ID=70331922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104197PA SG11202104197PA (en) | 2018-10-24 | 2019-10-24 | Methods and systems for manufacturing hematopoietic lineage cells |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210395684A1 (fr) |
EP (1) | EP3870189A4 (fr) |
JP (2) | JP2022512810A (fr) |
KR (1) | KR20210110570A (fr) |
CN (1) | CN113631699A (fr) |
AU (1) | AU2019368313A1 (fr) |
BR (1) | BR112021007748A2 (fr) |
CA (1) | CA3117464A1 (fr) |
IL (1) | IL282563A (fr) |
SG (1) | SG11202104197PA (fr) |
WO (1) | WO2020086889A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
EP4271798A1 (fr) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions et procédés de différenciation de cellules souches en cellules nk |
GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
WO2022187682A2 (fr) * | 2021-03-05 | 2022-09-09 | The Children's Medical Center Corporation | Différenciation de cellules nk sans stroma à partir de cellules souches pluripotentes humaines |
CN113265377B (zh) * | 2021-06-11 | 2023-01-24 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种动脉内皮促进功能性t细胞再生的方法 |
WO2023019213A1 (fr) * | 2021-08-13 | 2023-02-16 | Simcere Innovation, Inc. | Culture tridimensionnelle de cellules souches pluripotentes pour produire des cellules souches hématopoïétiques |
KR20240141196A (ko) * | 2022-01-31 | 2024-09-25 | 가부시키가이샤 헤리오스 | 천연 킬러 세포의 제조 방법 |
WO2023194488A1 (fr) * | 2022-04-05 | 2023-10-12 | Celyntra Therapeutics Sa | Production a grande échelle de csh issues de cspi et de leur progéniture |
WO2023240248A2 (fr) * | 2022-06-09 | 2023-12-14 | Umoja Biopharma, Inc. | Compositions et méthodes pour différenciation de cellule nk |
WO2024036148A1 (fr) * | 2022-08-08 | 2024-02-15 | A2 Biotherapeutics, Inc. | Compositions et méthodes pour traitement de cancers du sang |
WO2024044347A1 (fr) * | 2022-08-25 | 2024-02-29 | Trailhead Biosystems Inc. | Procédés et compositions pour générer des cellules endothéliales à partir de cellules souches pluripotentes |
WO2024059070A1 (fr) * | 2022-09-13 | 2024-03-21 | R.P. Scherer Technologies, Llc | Procédé de différenciation de cellules souches pluripotentes en précurseurs et cellules souches hématopoïétiques |
WO2024076030A1 (fr) * | 2022-10-05 | 2024-04-11 | 주식회사 듀셀바이오테라퓨틱스 | Procédé de production de plaquettes |
KR102543304B1 (ko) * | 2022-10-05 | 2023-06-14 | 주식회사 듀셀바이오테라퓨틱스 | 혈소판 생성능이 우수한 세포 및 혈소판의 제조방법 |
WO2024143555A1 (fr) * | 2022-12-28 | 2024-07-04 | 国立大学法人千葉大学 | Procédé de régulation de degré de cytodifférenciation |
KR102686850B1 (ko) * | 2023-03-29 | 2024-07-19 | 주식회사 듀셀바이오테라퓨틱스 | 혈소판의 제조 방법 |
CN116875538B (zh) * | 2023-06-25 | 2024-09-24 | 昆明理工大学 | 培养基及用其诱导分化胚外内胚层和胚外中胚层的方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001034797A1 (fr) * | 1999-11-10 | 2001-05-17 | Center For Advanced Science And Technology Incubation, Ltd. | Procede de preparation de fractions cellulaires contenant des hemangioblastes |
EP2088190A4 (fr) * | 2006-11-09 | 2011-01-05 | Japan Government | Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire |
US8372642B2 (en) * | 2009-02-27 | 2013-02-12 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
US9150829B2 (en) * | 2009-03-20 | 2015-10-06 | Agency For Science, Technoloy And Research | Culture of pluripotent and multipotent cells on microcarriers |
CN102985531B (zh) * | 2010-09-10 | 2019-04-23 | 国立大学法人东京大学 | 涉及由多能干细胞向血细胞分化的培养方法 |
WO2013075222A1 (fr) * | 2011-11-21 | 2013-05-30 | University Health Network | Populations de progéniteurs hématopoïétiques et procédés d'enrichissement de cellules souches associé en ceux-ci |
US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
EP3068875B1 (fr) * | 2013-11-13 | 2020-05-13 | Cornell University | Cellules endothéliales hématopoïétiques post-natales ainsi que leur isolement et leur utilisation |
US11090333B2 (en) * | 2015-09-14 | 2021-08-17 | Baylor College Of Medicine | Immune stimulatory function and anti-tumor activity of TGF-β primed myeloid derived suppressor cells (MDSC) |
WO2017192708A1 (fr) * | 2016-05-03 | 2017-11-09 | The Children's Medical Center Corporation | Cellules souches et progénitrices hématopoïétiques dérivées de cellules endothéliales hémogéniques |
CN106554942A (zh) * | 2016-11-18 | 2017-04-05 | 吉林省拓华生物科技有限公司 | 一种高效的临床级cd56+群免疫细胞的制备方法 |
-
2019
- 2019-10-24 BR BR112021007748-0A patent/BR112021007748A2/pt unknown
- 2019-10-24 CN CN201980084158.2A patent/CN113631699A/zh active Pending
- 2019-10-24 JP JP2021522492A patent/JP2022512810A/ja active Pending
- 2019-10-24 SG SG11202104197PA patent/SG11202104197PA/en unknown
- 2019-10-24 CA CA3117464A patent/CA3117464A1/fr active Pending
- 2019-10-24 WO PCT/US2019/057929 patent/WO2020086889A1/fr unknown
- 2019-10-24 AU AU2019368313A patent/AU2019368313A1/en active Pending
- 2019-10-24 EP EP19877359.0A patent/EP3870189A4/fr active Pending
- 2019-10-24 KR KR1020217015468A patent/KR20210110570A/ko unknown
- 2019-10-24 US US17/287,281 patent/US20210395684A1/en active Pending
-
2021
- 2021-04-22 IL IL282563A patent/IL282563A/en unknown
-
2024
- 2024-01-22 JP JP2024007289A patent/JP2024026891A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3870189A4 (fr) | 2022-09-28 |
US20210395684A1 (en) | 2021-12-23 |
IL282563A (en) | 2021-06-30 |
AU2019368313A1 (en) | 2021-05-20 |
JP2024026891A (ja) | 2024-02-28 |
WO2020086889A1 (fr) | 2020-04-30 |
CN113631699A (zh) | 2021-11-09 |
EP3870189A1 (fr) | 2021-09-01 |
CA3117464A1 (fr) | 2020-04-30 |
BR112021007748A2 (pt) | 2021-07-27 |
KR20210110570A (ko) | 2021-09-08 |
JP2022512810A (ja) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282563A (en) | Methods and systems for the production of lineage cells related to the formation of blood cells | |
IL291373A (en) | Methods and systems for growing cells in culture | |
EP3710876A4 (fr) | Systèmes et procédés de fabrication de cellules de guide d'ondes | |
IL282735A (en) | Preparations and methods for t-cell engineering | |
SG11202101994XA (en) | Genetically engineered hematopoietic stem cells and uses thereof | |
EP3657629C0 (fr) | Systèmes de gestion de batteries et procédés associés | |
EP3706784A4 (fr) | Compositions et procédés de production de lymphocytes t | |
EP3619234A4 (fr) | Compositions et méthodes pour thérapies par cellules adoptives | |
EP3472178A4 (fr) | Compositions et procédés pour la déplétion des cellules cd117+ | |
EP3370741A4 (fr) | Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques | |
EP3273976A4 (fr) | Cellules t modifiées, leurs procédés de préparation et utilisation | |
IL266251A (en) | Immunosuppressive mesenchymal cells and methods of their creation | |
EP3686275A4 (fr) | Lymphocyte t d'édition de gènes et utilisation associée | |
IL287874A (en) | Preparations and methods for producing t cells | |
EP3710841A4 (fr) | Procédés et systèmes de gestion de batteries à cellules multiples | |
IL275014A (en) | Cell systems using spheroids and methods for their preparation and use | |
EP3324982A4 (fr) | Cellules souches hématopoïétiques exprimant pd-l1 leurs utilisations | |
GB201902230D0 (en) | Storage systems and methods | |
EP3850336A4 (fr) | Cellules à circulation et procédés associés | |
EP3688144A4 (fr) | Cellules cd1d et tcr-nkt | |
IL286873A (en) | Cell culture systems and their use | |
IL279563A (en) | Flow cells and related systems and methods | |
EP3307873A4 (fr) | Cellules hématopoïétiques et leurs méthodes d'utilisation et de préparation | |
EP3573627A4 (fr) | Systèmes et procédés d'expansion de cellules hématopoïétiques au moyen d'hydrogels | |
IL271012A (en) | T cells with reduced surface fucosylation and methods for their preparation and use |